netFormulary NHS
Sunderland Joint Formulary
NHS Sunderland Clinical Commissioning Group
South Tyneside and Sunderland NHS Foundation Trust
 Search
 Formulary Chapter 3: Respiratory system - Full Chapter
Chapter Links...
 Details...
03.04.02  Expand sub section  Allergen Immunotherapy
Benralizumab (Fasenra®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
  • Approved for treating severe eosinophilic asthma in adults in line with NICE 
  • Link  NICE TA 565: Benralizumab for treating severe eosinophilic asthma
       
    Grass pollen extract (Grazax)
    View adult BNF View SPC online
    Formulary
    Amber

    Oral lyophilisate containing grass pollen extract 75,000 units

     
       
    Mepolizumab (Nucala)
    View adult BNF View SPC online View SMC online
    Formulary
    Red
    High Cost Medicine

    Powder for solution for injection: 100mg

     
    Link  NICE TA 431: Mepolizumab for treating severe refractory eosinophilic asthma
       
    03.04.02  Expand sub section  Omalizumab
    Omalizumab (Xolair)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Prefilled syringe: 75mg/0.5ml, 150mg/1ml

    Review effectiveness after 16 weeks of commencing treatment 
    Link  NICE TA278: Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201)
    Link  NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
       
    Reslizumab
    View adult BNF View SPC online
    Formulary
    Red

    Vials: 25mg, 100mg

     
    Link  NICE TA 479: Reslizumab for treating severe eosinophilic asthma
       
     ....
     Non Formulary Items
    Bee and Wasp Allergen Extracts  (Pharmalgen)

    View adult BNF View SPC online
    Non Formulary
     
    Grass and Tree Pollen Extract  (Pollinex®)

    View adult BNF View SPC online
    Non Formulary
     
    House dust mite allergen immunotherapy  (Mitizax)

    View adult BNF View SPC online
    Non Formulary
     
      
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to SPCs
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Red

    Drugs for hospital use or use by a specialist within specialist centre only. Initiation and monitoring of treatment should remain under the total responsibility of the appropriate hospital clinician or specialist. These drugs should only be prescribed under the direct supervision of that clinician or specialist and are not suitable for shared care arrangements. The drug should be supplied via the hospital or specialist centre for the duration of treatment.   

    Amber

    These are specialist drugs which must be initiated by secondary care specialist prescribers, but with the potential to transfer prescribing to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care. For these drugs, in order to ensure patient safety, some aspects of care must remain with the specialist due to their complexity e.g. monitoring of disease or drug response. Other more routine aspects can be transferred to the GP e.g. monitoring of adverse effects and supply of the medicine. The specific responsibilities of the specialist and GP are defined in the shared care agreement for each drug. Shared care agreements are still under development for some amber drugs. Until these are available, it would be expected that any shared care request from secondary care to a GP would be accompanied by written information which defines prescribing and monitoring responsibilities. The hospital specialist should also provide the GP with enough information and support to allow the safe transfer and ongoing management of prescribing into primary care.   

    Green +

    Drugs which should usually be initiated in secondary care, or by a specialist clinician, but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case.  

    Green

    These are defined as new and established drugs, which may be prescribed, initiated, changed or maintained on FP10 by the GP and, if appropriate, discontinued without recourse to secondary care. N.B. DRUGS NOT IDENTIFIED IN THE FORMULARY BY A RED, AMBER OR GREEN+ SYMBOL ARE CLASSIFIED AS GREEN.   

    netFormulary